Dominance of specific lung bacteria over microbiota diversity in COVID-19 clinical trajectories
The Journal of Infection in Developing Countries · 2025
DOI: 10.3855/jidc.21099 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Qiaoyu Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Medical Sciences, Department of Occupational Health, Shanxi Medical University, Taiyuan, Shanxi, China. Hauptthemen laut MEDLINE: COVID-19, Lung, Microbiota, Bacteria. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Health Commission of Shanxi Province.
Abstract (Originalsprache)
Introduction
This study investigates the impact of lung microbiota on COVID-19 outcomes. Methodology: Clinical data and bronchoalveolar lavage fluid (BALF) data and bronchoalveolar lavage fluid (BALF) samples were retrospectively collected from 40 COVID-19 patients for Targeted Next-generation Sequencing (TNGS). Microbial diversity was then analyzed across different clinical severity groups. Additionally, biomarkers were identified using Linear Discriminant Analysis Effect Size (LEfSe) and evaluated by Receiver Operating Characteristic (ROC) - Area Under the Curve (AUC).
Results
The patients were classified by severity as mild (n = 3), moderate (n = 13), severe (n = 16), or critical (n = 8) symptoms. The α-diversity of respiratory flora showed no significant differences between groups (p > 0.05). While β-diversity analysis revealed significant compositional distinctions (p < 0.05). Critically ill patients had higher levels of Pseudomonas aeruginosa compared to other groups, ROC-plot AUC value of 0.856. Patients were then categorized into two outcome-based groups: Non-survivors (n = 5) and Survivors (n = 35). No significant differences in α-diversity of respiratory flora were observed between the two groups (p > 0.05), while β-diversity revealed distinct compositional differences (p < 0.05). Furthermore, the ROC curve for Pseudomonas aeruginosa (AUC = 0.846) indicated its predictive value for mortality.
Conclusions
This study has elucidated the characteristics of pulmonary microbiota across different COVID-19 severities, identifying bacteria associated with severe illness, mortality, and relevant clinical markers. The lung microbiota exhibits low diversity, making the pulmonary microecology more vulnerable to disruption. Therefore, invasive species may influence clinical outcomes in affected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Academy of Medical Sciences, Department of Occupational Health, Shanxi Medical University, Taiyuan, Shanxi, China.
- The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China.
- NHC Key Laboratory of Pneumoconiosis, Shanxi Key Laboratory of Respiratory Diseases. Department of Pulmonary and Critical Care Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Förderung
- National Natural Science Foundation of China
- Health Commission of Shanxi Province
Zitieren
APA
Li, Q., Liu, J., Zhang, J., Xiong, T., Shi, Y., & Yu, X. (2025). Dominance of specific lung bacteria over microbiota diversity in COVID-19 clinical trajectories. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.21099
Vancouver
Li Q, Liu J, Zhang J, Xiong T, Shi Y, Yu X. Dominance of specific lung bacteria over microbiota diversity in COVID-19 clinical trajectories. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.21099
BibTeX
@article{Li2025,
author = {Li, Qiaoyu and Liu, Jingjing and Zhang, Jingfen and Xiong, Tao and Shi, Yiwei and Yu, Xiao},
title = {Dominance of specific lung bacteria over microbiota diversity in COVID-19 clinical trajectories},
journal = {The Journal of Infection in Developing Countries},
year = {2025},
doi = {10.3855/jidc.21099}
}
EUVIMED